Table 3.

Selected active clinical trials of immunotherapy and chemoradiation for ES-SCLC.

ClinicalTrials.gov Trial ID	Intervention	Primary end point	Study status	Study design
NCT03971214 (PICARES)	Post-CRT (EP) PD-L1 inhibitor	Adverse events, remission rate	Active, not yet recruiting	Phase I
NCT02402920	Post-EP chemotherapy pembrolizumab and BID RT	Safety of pembrolizumab with radiation	Active, Recruiting	Phase I
NCT03043599	Post-EP chemotherapy consolidation ipilimumab and nivolumab with RT	Phase I—Confirmation of ipilimumab and nivolumab dose Phase II—PFS	Active, not recruiting	Phase I/II
NCT03382561	CRT (EP) ± concurrent nivolumab	PFS	Active, not recruiting	Phase II
NCT03670056	Ipilimumab and nivolumab for recurrence after CRT (EP)	Change in ratio of Teff/Treg cells	Active, not recruiting	Phase II

CRT, chemoradiotherapy; EP, etoposide-cisplatin; BID, twice daily treatments; RT, radiotherapy; PFS, progression-free survival; Teff, effector T-cells; Treg, regulatory T-cells.